Peptides After the FDA's July Vote: What Actually Changed, and What Didn't

Peptides are having a moment. They come up in intake visits now the way GLP-1 medications did three years ago — someone read about one, a podcast mentioned it, a friend is injecting something they ordered online. Then in July, an FDA advisory committee made a decision that got covered as though peptides had just been approved.

They weren't. But something real did happen, and it's worth understanding accurately, because the gap between what the vote actually did and how it's being described is where people get hurt.

What happened in July

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met to consider whether seven peptides should become eligible for pharmacy compounding under Section 503A — BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and emideltide (also called DSIP).¹

The committee voted to recommend six of the seven. Only emideltide was turned down.²

What made this notable to people who follow FDA proceedings is that the agency's own scientific reviewers had recommended against adding any of the seven. Their briefing materials cited studies that were short, small, and insufficient to establish safety or efficacy for the proposed uses. The panel voted the other way, narrowly, on all six.³

What the vote did not do

This is the part that matters most, and the part most coverage skipped.

It did not make these peptides FDA-approved. None of them is an approved drug. A compounded medication is not an FDA-approved medication — the agency doesn't review individual compounded preparations for safety, effectiveness, or quality before they reach a patient.

It did not make them legal to compound. Advisory committee votes are non-binding recommendations. For any of these substances to actually become eligible, the FDA has to accept the recommendation and then go through proposed and final rulemaking — a process with public comment periods that takes time and doesn't have a guaranteed outcome.⁴

It did not represent new evidence. Nothing about the underlying science changed between June and July. The same studies existed before the vote as after it.

It's also worth knowing that the reconstituted committee drew scrutiny over its composition, with more members who prescribe, produce, or promote peptides than previous panels had.³ That doesn't invalidate the outcome, but it's context worth having when a panel overrides its own agency's scientists.

What the evidence actually shows

Take BPC-157, the peptide I get asked about most. A systematic review published in the HSS Journal in 2025 set out to synthesize everything available on it for musculoskeletal use. The researchers screened 544 articles.

One human clinical study met inclusion criteria. The other 35 studies included were animal models.⁵

That single human study was a retrospective look at 12 patients who received an injection for chronic knee pain, of whom 7 reported improvement lasting more than six months.⁵ That is not nothing — but it is a retrospective case series of twelve people, not a randomized controlled trial. As of now there is still no published, peer-reviewed randomized controlled trial of BPC-157 in humans for any indication.

The preclinical work is genuinely interesting. In animal models BPC-157 improved healing outcomes across muscle, tendon, ligament, and bone injuries, and there are plausible mechanisms behind it.⁵ But animal results don't reliably translate to people, and "promising in rats" is a different statement than "works in women in their forties."

I'd say something similar about most of the peptides in the wellness conversation right now. The mechanism stories are compelling. The human outcome data is thin.

The part nobody markets

Peptides are widely sold as "research use only" products — a category that exists specifically to sidestep the regulations that apply to medications. Those products aren't manufactured under the standards that apply to prescription drugs, and there's no independent verification that the vial contains what the label says, at the dose it says, without contaminants.

The FDA has separately warned patients about unapproved products in this general space and advised obtaining prescription medications through licensed providers and state-licensed pharmacies.⁶

If you're considering a peptide, the sourcing question isn't a footnote. Where it came from, who made it, and what standards applied to it are as clinically relevant as the peptide itself.

Where I land

Some peptides are genuinely well established. Insulin is a peptide. So are GLP-1 receptor agonists, oxytocin, and calcitonin — decades of use, real trials, clear indications.⁷ I use those where they're indicated, without hesitation.

The newer category is different, and I treat it differently. When someone asks me about BPC-157 or MOTS-c, my answer isn't "no" and it isn't an enthusiastic yes. It's that the evidence is mostly preclinical, the sourcing landscape is genuinely risky, the regulatory status is unsettled, and any decision has to account for all three alongside your actual history and what else is going on with you.

That's a less satisfying answer than most of the internet gives. It's also the accurate one.

Peptide management, when it's appropriate, is part of ongoing care within the Integrative Primary Care Membership — alongside hormone and GLP-1 management — rather than a standalone program you buy off a menu. That's deliberate. Whether a peptide makes sense for you isn't a product decision; it's a clinical one that depends on everything else in your picture.

If you want the broader background on what peptides are and how they work, I've written a general overview here.

If you've been reading about a specific peptide and want to think it through with someone who'll tell you where the evidence actually sits, that's a reasonable thing to bring to a visit or a free intro call.

Sources

1. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Accessed September 2026.
2. Holland & Knight. FDA Advisory Committee Endorses Compounding of Certain Peptides. August 2026.
3. American Journal of Managed Care. FDA Panel Backs 6 Peptides for Compounding. 2026.
4. Buchanan Ingersoll & Rooney PC. FDA Advisory Committee Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead. 2026.
5. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485–495. doi:10.1177/15563316251355551
6. U.S. Food and Drug Administration. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. 2025.
7. Rossino G, Marchese E, Galli G, et al. Peptides as Therapeutic Agents: Challenges and Opportunities in the Green Transition Era. Molecules. 2023;28(20):7165. doi:10.3390/molecules28207165